Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101195 | 0.88 | MTNR1A (0.40) | MTNR1AMTNR1B | |
| SCHEMBL7098613 | 0.84 | MTNR1A (0.40) | MTNR1ATP53 | |
| SCHEMBL7201899 | 0.84 | MTNR1A (0.56) | MTNR1AMTNR1BHTR2CSMN1; SMN2 | |
| SCHEMBL7198759 | 0.79 | MTNR1A (0.52) | MTNR1AMTNR1BTP53SMN1; SMN2 | |
| SCHEMBL7021424 | 0.76 | MTNR1A (0.48) | MTNR1AMTNR1BTP53SMN1; SMN2 | |
| SCHEMBL8113907 | 0.75 | AKR1C2 (0.47) | MTNR1ASMN1; SMN2 | |
| SCHEMBL8135950 | 0.74 | MTNR1A (0.40) | MTNR1AMTNR1B | |
| SCHEMBL5349885 | 0.74 | MTNR1A (0.51) | MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5338460 | 0.74 | MTNR1A (0.51) | MTNR1AMTNR1B | |
| SCHEMBL7204042 | 0.73 | TSHR (0.43) | MTNR1ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-0998471-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998052935-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | MTNR1A 1/4885MTNR1B 2/4885HTR2C 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.